International Therapeutics is a privately held biotechnology company in Seattle that is developing novel drugs and therapeutic approaches in the fight against HIV-1, the virus that causes AIDS. To date, ITI has been funded from private investors and NIH grants. In 2001, ITI was awarded a Phase II SBIR grant from the National Institutes of Health (see press release on News page) to conduct preclinical studies on compounds that prevent the virus’s genes from moving into a cell’s nucleus in a process called nuclear entry. In addition, ITI is developing innovative proprietary technologies, like ProxiQuant™, to produce near term revenue. ITI is currently securing institutional financing for the growth and development of the Company and its technologies.

Financing History:
If you would like more information about the Company and its financing please direct you inquiries to:

Mr. Bret MacPherson
Vice President of Operations
International Therapeutics, Inc.
600 Broadway
Suite 510
Seattle, WA 98122

Back to top